Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

NCT06948955 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Interventions

DRUG: Bezuclastinib
DRUG: Sunitinib

Sponsor

Cogent Biosciences, Inc.